Biosimilars

In recent years, biologics — drugs derived from living culture systems — have become increasingly significant in the fight against a plethora of conditions. Unfortunately, the efficiency of these drugs comes at a cost. A daily dose of a biologic drug costs, on average, 22 times more than conventional small-molecule drugs. Therefore, biosimilars are developed to make them more accessible. Lung cancer is an example where the development of biosimilars could increase treatment options available for patients.

This webinar presents a downstream processing workflow for recombinant human insulin production from E. coli. Learn how proinsulin and insulin can be purified.

In this podcast, biosimilar key opinion leader Dr. Paul Rhyne provides an overview of the current state of biosimilars and their global impact. Leveraging his 20+ years of experience in developing biologics, he discusses how cost and patient access play a big role in this new field of research.

It is hoped that the development of biosimilars will lead to more accessible and cost-effective treatment options. Here we explore the current opportunities for biosimilars in rheumatoid arthritis and discuss the opportunities and concerns tied to their use.

Biosimilars are gaining in popularity and estimates predict that the U.S. could save between $40–250 billion in healthcare costs over the next decade by switching from biologics to biosimilars. See how biosimilars have gained in popularity recently, the challenges the U.S. faces in developing them, and what the future holds.

In this podcast, biosimilar expert, Amanda Turner, provides an in-depth explanation of the various in vitro assays used in biosimilar development and the importance of choosing the right assay type and components to achieve success.

Is the hype surrounding biosimilars real or simply a hopeful view on an exceedingly expensive drug market? Read this article to find out more about biosimilars and understand the challenges facing the biosimilars industry.